Leuprolide Acetate
Drug
TOLMAR, INC.
Total Payments
$1.7M
Transactions
690
Doctors
8
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $1.1M | 528 | 4 |
| 2022 | $350,830 | 113 | 1 |
| 2021 | $216,535 | 44 | 0 |
| 2020 | $17,910 | 5 | 4 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.7M | 687 | 100.0% |
| Food and Beverage | $458.78 | 3 | 0.0% |
Payments by Type
Research
$1.7M
687 transactions
General
$458.78
3 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| TOL2506A | TOLMAR, INC. | $1.4M | 5 |
| TOL2506A | Tolmar, Inc. | $224,730 | 0 |
| TOL2506A-EXT | TOLMAR, INC. | $67,270 | 0 |
Top Doctors Receiving Payments for Leuprolide Acetate
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Wichita, KS | $1.5M | 659 |
| , M.D | Hematology & Oncology | Miami Beach, FL | $131,690 | 23 |
| , MD | Hematology & Oncology | Houston, TX | $9,200 | 2 |
| , MD | Medical Oncology | Denver, CO | $3,875 | 1 |
| , MD | Medical Oncology | Chicago, IL | $3,875 | 1 |
| Hannah Linden | Medical Oncology | Seattle, WA | $960.00 | 1 |
| , MD | Hematology & Oncology | Goodyear, AZ | $181.60 | 1 |
| , M.D | Hematology & Oncology | Billings, MT | $146.17 | 1 |
| , MD | Hematology & Oncology | Louisville, KY | $131.01 | 1 |
Ad
Manufacturing Companies
- TOLMAR, INC. $1.4M
- Tolmar, Inc. $225,189
Product Information
- Type Drug
- Total Payments $1.7M
- Total Doctors 8
- Transactions 690
About Leuprolide Acetate
Leuprolide Acetate is a drug associated with $1.7M in payments to 8 healthcare providers, recorded across 690 transactions in the CMS Open Payments database. The primary manufacturer is TOLMAR, INC..
Payment data is available from 2020 to 2023. In 2023, $1.1M was paid across 528 transactions to 4 doctors.
The most common payment nature for Leuprolide Acetate is "Unspecified" ($1.7M, 100.0% of total).
Leuprolide Acetate is associated with 3 research studies, including "TOL2506A" ($1.4M).